Evidence map›Paper›PMID 30091177›Full record

ReviewClinical pharmacology and therapeutics2018

Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.

Maciej J Zamek-Gliszczynski, Mitchell E Taub, Paresh P Chothe, Xiaoyan Chu, Kathleen M Giacomini, Richard B Kim, Adrian S Ray, Sophie L Stocker, Jashvant D Unadkat, Matthias B Wittwer and 5 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical pharmacology and therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 1 synthesis or guideline pooled it, 226 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Substrate-specific inhibition of organic cation transporter 1 revealed using a multisubstrate drug cocktail.Drug metabolism and disposition: the biological fate of chemicals · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 8 countries.

Maciej J Zamek-GliszczynskiQuantitative Drug Disposition, GlaxoSmithKline, King of Prussia, Pennsylvania, USA.
Mitchell E TaubDrug Metabolism and Pharmacokinetics, Boehringer Ingelheim, Ridgefield, Connecticut, USA.
Paresh P ChotheDrug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, Boston, Massachusetts, USA.
Xiaoyan ChuDepartment of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Kenilworth, New Jersey, USA.
Kathleen M GiacominiDepartment of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, California, USA.
Richard B KimDivision of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.
Adrian S RayClinical Research, Gilead Sciences, Foster City, California, USA.
Sophie L StockerDepartment of Clinical Pharmacology & Toxicology, St Vincent's Hospital, Sydney, NSW, Australia & St Vincent's Clinical School, UNSW Sydney, NSW, Australia.
Jashvant D UnadkatDepartment of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Matthias B WittwerRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Cindy XiaDrug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International, Cambridge, Massachusetts, USA.
Sook-Wah YeeDepartment of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, California, USA.
Lei ZhangOffice of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
Yan ZhangDrug Metabolism Pharmacokinetics & Clinical Pharmacology, Incyte, Wilmington, Delaware, USA.
International Transporter Consortium
University of California, San Francisco · USAstraZeneca (United States) · USBoehringer Ingelheim (Germany) · DECenter for Drug Evaluation and Research · USGilead Sciences (United States) · USGlaxoSmithKline (United Kingdom) · GBIncyte (United States) · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USRoche (Switzerland) · CHSt Vincent's Hospital Sydney · AUUniversity of Washington · USVertex Pharmaceuticals (United States) · USWestern University · CA

Funding

Understanding Fetal Exposure to Cannabinoids Through In Vitro and In Vivo StudiesP01DA032507 · NIDA · UNIVERSITY OF WASHINGTON · PI UNADKAT, JASHVANT D · 2013 to 2023
$12.4M
NIDA NIH HHS P01 DA032507
6 · The paper itself

Abstract

This white paper provides updated International Transporter Consortium (ITC) recommendations on transporters that are important in drug development following the 3

Indexed as

PharmacokineticsAnimalsDrug DevelopmentDrug InteractionsHumansMembrane Transport ModulatorsMembrane Transport ProteinsModels, BiologicalPharmaceutical PreparationsRisk AssessmentMembrane Transport ModulatorsMembrane Transport ProteinsPharmaceutical Preparations

Identifiers

PMID30091177
PMCPMC8211378
OpenAlexW2887655204

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.